SEC Comment Letter for Stealth BioTherapeutics Corp (CIK 0001696396) — Jun 26, 2020

Stealth BioTherapeutics Corp (CIK 0001696396)
Date: June 26, 2020 · CIK: 0001696396 · Accession: 0000000000-20-005762

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-239356

Date

June 26, 2020

Author

Not clearly detected

Form

UPLOAD

Company

Stealth BioTherapeutics Corp (CIK 0001696396)

Letter

United States securities and exchange commission logo June 26, 2020 Irene McCarthy Chief Executive Officer Stealth BioTherapeutics Corp c/o Intertrust Corporate Services (Cayman) Limited 190 Elgin Avenue, George Town Grand Cayman KY1-9005 Cayman Islands Re:Stealth BioTherapeutics Corp Registration Statement on Form F-1 Filed June 22, 2020 File No. 333-239356 Dear Ms. McCarthy: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason L. Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Rosemary G. Reilly, Esq.

Show Raw Text

United States securities and exchange commission logo
June 26, 2020
Irene McCarthy
Chief Executive Officer
Stealth BioTherapeutics Corp
c/o Intertrust Corporate Services (Cayman) Limited
190 Elgin Avenue, George Town
Grand Cayman
KY1-9005 Cayman Islands
Re:Stealth BioTherapeutics Corp
Registration Statement on Form F-1
Filed June 22, 2020
File No. 333-239356
Dear Ms. McCarthy:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jason L. Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Rosemary G. Reilly, Esq.

SecProbe.io